CD38 and Miyoshi myopathy: We included the anti-CD38 antibody daratumumab in monotherapy (in this case EMM cells showed CD38 expression) and the combination of lenalidomide and dexamethasone with or without the proteosome inhibitor carfilzomib, as these schemes are recommended for the treatment of MM in patients who have received at least one previous therapy.